Valganciclovir in cytomegalovirus prophylaxis in renal transplant recipients


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Aim. Estimation of efficacy of prophylaxis of cytomegalovirus infection with valganciclovir in renal transplant recipients. Methods. Retrospective study included 349 renal transplant recipients: 17i of them received valganciclovir during 3 - 6 months. Patients, who received tacrolimus, more frequently used tacrolimus, those, who did not -cyclosporine. Median follow-up period duration was > 2 years (25,8 [і2,5; 40,6] months in valganciclovir group, 65.4 [50,6; 97,4] months in control group). Results. Valganciclovir use lead to decrease of frequency of active cytomegalovirus infection during 12 months of follow-up (7,0 % vs 22,6 %, p < 0,001), frequency of replication of all herpes-group viruses (9,2 % vs 32,4 %, p < 0,001); trend to decrease of all pneumonias was also observed (9,7 % vs 16 %, p = 0,ii). 1- and 2-year event-free survival was also higher in valganciclovir group (1-year: 78.4 % vs 65,2 %, P = 0,006; 2-year: 76,6 % VS 63,5 %, P = 0,009). Conclusion. Use of valganciclovir in renal transplant recipients leads to decrease of frequency of active cytomegalovirus infection and increase in event-free survival.

Texto integral

Acesso é fechado

Bibliografia

  1. Очерки клинической трансплантологии / Под ред. С.В. Готье. М. — Тверь, ООО «Издательство «Триада», 2009. 360 с.
  2. Трансплантация почки / Пер. с англ. под ред. Я.Г. Мойсюка. — М., ГЭОТАР-Медиа, 2013. 848 с.
  3. Harvala H., Stewart C., Muller K. et al. High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy // J. Med. Virol. — 2013; 85(5):893-898.
  4. Rubin R.H. The pathogenesis and clinical management of cytomegalovirus infection in the organ transplant recipient: The end of the ‘silo hypothesis’ // Curr. Opin. Infect. Dis. — 2007; 20: 399-407.
  5. Egli A., Binggeli S., Bodaghi S. et al. Cytomegalovirus and polyomavirus BK posttransplant // Nephrol. Dial. Transplant. — 2007; 22 (Suppl 8): viii72-viii82.
  6. Toupance O., Bouedjoro-Camus M.C., Carquin J. et al. Cytomegalovirus-related disease and risk of acute rejection in renal transplant recipients: a cohort study with case-control analyses// Transpl. Int. — 2000; 6: 413—419.
  7. Hjelmesaeth J., Muller F., Jenssen T. et al. Is there a link between cytomegalovirus infection and new-onsetpost transplantation diabetes mellitus? Potential mechanisms of virus induced beta-cell damage // Nephrol. Dial. Transplant. — 2005; 20: 2311—2315.
  8. Courivaud C., Bamoulid J., Chalopin J.M. et al. Cytomegalovirus exposure and cardiovascular disease in kidney transplant recipients // J. Infect. Dis. — 2013; 207(10):1569—1575.
  9. Fellay J., Venetz J.P., Pascual M. et al. Treatment of cytomegalovirus infection or disease in solid organ transplant recipients with valganciclovir // Am. J. Transplant. — 2005; 5 (7):1781—1782.
  10. Valentine V.G., Weill D., Lombard G.A. et al. Ganciclovir for cytomegalovirus: A call for indefinite prophylaxis// Am. J. Transplant. — 2007; 7 (S2): 505.
  11. Boudreault A.A., Xie H., Rakita R.M. et al. Risk factors for late-onset cytomegalovirus disease in donor seropositive/recipient seronegative kidney transplant recipients who receive antiviral prophylaxis // Transpl. Infect. Dis. — 2011; 13(3): 244—249.
  12. Papasotiriou M., Papachristou E., Marangos M. et al. Cytomegalovirus polyradiculopathy of late onset in a young renal transplant recipient // Clin. Nephrol — 2013; 80(1):75—78.
  13. Humar A., Lebranchu Y., Vincenti F. et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients//Am. J. Transplant. — 2010; 10: 1228—1237.
  14. Luan F.L., Stuckey L.J., Park J.M. et al. Six-month prophylaxis is cost effective in transplant patients at high risk for cytomegalovirus infection // J. Am. Soc. Nephrol. — 2009; 20(11): 2449—2458.
  15. Witzke O., Hauser I.A., Bartels M. et al. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial // Transplantation. — 2012; 93(1): 61—68.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies